# Assessment of Drug Dosing Appropriateness in Hospitalized Chronic Kidney Disease Patients with Cardiovascular Diseases: A Cross-Sectional Study in the Al-Baha Region, Saudi Arabia (2023–2025)

**Authors:** Lina O. Abdelmagid, Saleh Alghamdi, Mohammad Algarni, Mohammad A. Albanghali, Zuheir Osman, Ahmed Alghamdi, Mohammed Alamri, Mohammed S. Alghamdi, Saeed A. Alzahrani, Fayez Alghamdi, Bassant Mohamed Barakat

PMC · DOI: 10.3390/jcm15062293 · Journal of Clinical Medicine · 2026-03-17

## TL;DR

This study examines how well drug doses are adjusted for kidney disease patients in Saudi Arabia, finding many prescriptions are inappropriate.

## Contribution

The study provides new insights into drug dosing practices for CKD patients in the Al-Baha region of Saudi Arabia.

## Key findings

- 85% of patients had at least one appropriately adjusted medication.
- Antibiotics were most commonly inappropriately adjusted, with 77% of inappropriate dose events.
- Commonly prescribed drugs like metformin and spironolactone were often inappropriately prescribed to CKD patients.

## Abstract

Background/Objectives: For patients diagnosed with chronic kidney disease (CKD), it is important to follow guidelines addressing dose-adjustments for renally eliminated drugs to avoid complications related to toxicity and subtherapeutic effects. In Saudi Arabia, limited data are available regarding appropriate medication doses for CKD. In this study, we investigated the prevalence of inappropriately administered drugs in patients with CKD and examined factors associated with unadjusted renal dosing. Methods: A retrospective, cross-sectional, observational analysis (2023–2025) was conducted via a systematic electronic medical record review of hospitalized patients diagnosed with CKD and cardiovascular diseases (CVDs) in the Al-Baha region, Saudi Arabia. Medications were selected and evaluated for appropriate dosing based on creatinine clearance (CrCl). Medications were categorized as appropriately adjusted, inappropriately adjusted, unadjusted, or contraindicated. Results: A total of 440 patients (787 prescriptions) were included. At the patient level, 85% had at least one appropriately adjusted medication, 13% had at least one inappropriately adjusted medication, 30% had at least one medication that was not adjusted despite indication, 34% had at least one medication requiring no adjustment, and 17% had at least one contraindicated medication (categories are not mutually exclusive). At the prescription level, which was the primary analytic unit (N = 787), 48% of prescriptions were appropriately adjusted, 7% were inappropriately adjusted, 17% were not adjusted despite indication, 19% required no adjustment, and 10% were contraindicated. Antibiotics accounted for the largest share of inappropriate adjustments, representing 77% (43/56) of all inappropriate dose-adjustment events. In exploratory bivariate analyses, age was not statistically significantly associated with dosing outcomes (Holm-adjusted p = 0.145). Polypharmacy was highly prevalent (91% of patients) but was not significantly associated with any dosing outcome in these exploratory analyses, likely due to limited statistical power. Conclusions: Our results showed that several regularly prescribed drugs, including metformin, sitagliptin, ceftazidime, ciprofloxacin, and spironolactone, were inappropriately prescribed to patients with CKD. These dosing errors can be avoided by increasing clinicians’ and pharmacists’ awareness of appropriate dosage modifications essential for patients with CKD.

## Linked entities

- **Chemicals:** metformin (PubChem CID 4091), sitagliptin (PubChem CID 4369359), ceftazidime (PubChem CID 5481173), ciprofloxacin (PubChem CID 2764), spironolactone (PubChem CID 5833)
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Diseases:** CKD (MESH:D051436), toxicity (MESH:D064420), CVDs (MESH:D002318)
- **Chemicals:** creatinine (MESH:D003404), ciprofloxacin (MESH:D002939), sitagliptin (MESH:D000068900), spironolactone (MESH:D013148), ceftazidime (MESH:D002442), metformin (MESH:D008687)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13026596/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13026596/full.md

## References

72 references — full list in the complete paper: https://tomesphere.com/paper/PMC13026596/full.md

---
Source: https://tomesphere.com/paper/PMC13026596